

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4483334

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	FORTRESS BIOTECH, INC.	06/27/2017
RECEIVING PARTY DATA		
Name:	CHECKPOINT THERAPEUTICS, INC.	
Street Address:	2 GANSEVOORT STREET	
Internal Address:	9TH FLOOR	
City:	NEW YORK	
State/Country:	NEW YORK	
Postal Code:	10014	
PROPERTY NUMBERS Total: 2		
	Property Type	Number
	Application Number:	15636610
	Application Number:	62356105
CORRESPONDENCE DATA		
Fax Number:	(202)672-5399	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	202-672-5300	
Email:	ipdocketing@foley.com, swalker@foley.com	
Correspondent Name:	GILBERTO M. VILLACORTA	
Address Line 1:	FOLEY & LARDNER LLP	
Address Line 2:	3000 K STREET N.W., SUITE 600	
Address Line 4:	WASHINGTON, D.C. 20007-5109	
ATTORNEY DOCKET NUMBER:	099263-0801	
NAME OF SUBMITTER:	STELLA M. WALKER	
SIGNATURE:	/Stella M. Walker/	
DATE SIGNED:	06/28/2017	
Total Attachments: 2		
source=ASSIGNMENT_FORTRESS_TO_CHECKPOINT#page1.tif		
source=ASSIGNMENT_FORTRESS_TO_CHECKPOINT#page2.tif		

WORLDWIDE PATENT ASSIGNMENT

WHEREAS **Fortress Biotech, Inc.**, of 2 Gansevoort Street, 9th Floor, New York, New York 10014, USA (hereinafter "Assignor") is the owner of the rights to the patent application(s) listed below and to the invention(s) relating thereto in the United States of America and its territories and possessions thereof and all foreign countries;

WHEREAS **Checkpoint Therapeutics, Inc.**, of 2 Gansevoort Street, 9th Floor, New York, New York 10014, USA (hereinafter referred to as "Assignee") is desirous of acquiring all right, title and interest for the patent application(s) listed below and to the invention(s) relating thereto for the United States of America, its territories and possessions thereof and all foreign countries;

U.S. PATENT APPLICATION NO	FILING DATE	TITLE
62/356,105	6/29/2016	PD-L1-SPECIFIC ANTIBODIES AND METHODS OF USING THE SAME

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by Assignor, Assignor hereby assigns to Assignee the entire and exclusive right, title and interest in and to said inventions for the United States of America and all foreign countries, and in and to said worldwide patent applications listed above, including any and all divisional, continuation, continuation-in-part, reissues or extensions thereof, to be held and enjoyed by Assignee for its own use as fully and entirely as the same would have been held and enjoyed by Assignor had this assignment not been made; the Commissioner of Patents and Trademarks of the United States of America is hereby authorized to transfer the portion of the title indicated to said application to said Assignee in accordance herewith; this assignment being under covenant, not only that full power to make the same is had by the Assignor, but also that such assigned rights are not encumbered by any grant, license, or other right theretofore given; Assignor hereby undertakes to execute and deliver to Assignee upon request all lawful documents which may be requested by Assignee, and to furnish Assignee with all facts relating to said invention as may be requested.

The undersigned hereby grant the firm of FOLEY & LARDNER LLP, the power to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

ASSIGNOR:

Fortress Biotech, Inc.

Date: June 27, 2017

By: [Signature]
Name: Lindsay A. Rosenwald, MD
Title: President & CEO

Date: June 27, 2017

WITNESS: [Signature]

Date: June 27, 2017

WITNESS: [Signature]

ASSIGNEE:

Checkpoint Therapeutics, Inc.

Date: June 27, 2017

By: [Signature]
Name: James Oliviero
Title: President and CEO

Date: JUNE 27, 2017

WITNESS: [Signature]

Date: June 27, 2017

WITNESS: [Signature]